Mo Dimbil

628 total citations
7 papers, 455 citations indexed

About

Mo Dimbil is a scholar working on Toxicology, Pharmacology and Economics and Econometrics. According to data from OpenAlex, Mo Dimbil has authored 7 papers receiving a total of 455 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Toxicology, 3 papers in Pharmacology and 3 papers in Economics and Econometrics. Recurrent topics in Mo Dimbil's work include Pharmacovigilance and Adverse Drug Reactions (4 papers), Statistical Methods in Clinical Trials (3 papers) and Pharmaceutical industry and healthcare (3 papers). Mo Dimbil is often cited by papers focused on Pharmacovigilance and Adverse Drug Reactions (4 papers), Statistical Methods in Clinical Trials (3 papers) and Pharmaceutical industry and healthcare (3 papers). Mo Dimbil collaborates with scholars based in United States. Mo Dimbil's co-authors include Keith B. Hoffman, Nicholas P. Tatonetti, Christina N. Kraus, Beatrice A. Golomb, J. Nicholas O’Donnell, John W. Devlin, Nada S. Al‐Qadheeb, Jonathan Weinstock, Matthew S. Duprey and Christopher Madias and has published in prestigious journals such as PLoS ONE, Drug Safety and Journal of Managed Care & Specialty Pharmacy.

In The Last Decade

Mo Dimbil

7 papers receiving 442 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mo Dimbil United States	6	144	83	70	53	47	7	455
Hélène Théophile France	15	228 1.6×	71 0.9×	48 0.7×	171 3.2×	43 0.9×	28	602
Marie‐Blanche Valnet‐Rabier France	13	83 0.6×	47 0.6×	50 0.7×	86 1.6×	43 0.9×	28	478
Diogo Mendes Portugal	16	92 0.6×	100 1.2×	71 1.0×	96 1.8×	66 1.4×	40	796
Eileen Wu United States	11	95 0.7×	28 0.3×	32 0.5×	32 0.6×	31 0.7×	23	378
Andrea Belisari Italy	7	69 0.5×	29 0.3×	95 1.4×	21 0.4×	56 1.2×	23	462
Neil Dhopeshwarkar United States	10	124 0.9×	57 0.7×	47 0.7×	290 5.5×	31 0.7×	18	544
Kui Huang United States	13	70 0.5×	46 0.6×	11 0.2×	51 1.0×	29 0.6×	29	613
Hoi Y. Tong Spain	12	31 0.2×	37 0.4×	56 0.8×	120 2.3×	51 1.1×	26	385
C Proudlove United Kingdom	11	42 0.3×	60 0.7×	27 0.4×	23 0.4×	13 0.3×	15	466
Eric Hung United States	10	108 0.8×	22 0.3×	94 1.3×	54 1.0×	59 1.3×	15	335

Countries citing papers authored by Mo Dimbil

Since Specialization

Citations

This map shows the geographic impact of Mo Dimbil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mo Dimbil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mo Dimbil more than expected).

Fields of papers citing papers by Mo Dimbil

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mo Dimbil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mo Dimbil. The network helps show where Mo Dimbil may publish in the future.

Co-authorship network of co-authors of Mo Dimbil

This figure shows the co-authorship network connecting the top 25 collaborators of Mo Dimbil. A scholar is included among the top collaborators of Mo Dimbil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mo Dimbil. Mo Dimbil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Duprey, Matthew S., Nada S. Al‐Qadheeb, J. Nicholas O’Donnell, et al.. (2019). Serious Cardiovascular Adverse Events Reported with Intravenous Sedatives: A Retrospective Analysis of the MedWatch Adverse Event Reporting System. Drugs - Real World Outcomes. 6(3). 141–149. 5 indexed citations

2.

Dimbil, Mo, et al.. (2017). Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors. Drug Safety. 41(4). 357–361. 110 indexed citations

3.

Hoffman, Keith B., et al.. (2016). A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports. Drug Safety. 39(6). 561–575. 26 indexed citations

4.

Hoffman, Keith B., et al.. (2015). A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes. Journal of Managed Care & Specialty Pharmacy. 21(12). 1134–1143c. 5 indexed citations

5.

Hoffman, Keith B., et al.. (2014). Stimulated Reporting: The Impact of US Food and Drug Administration-Issued Alerts on the Adverse Event Reporting System (FAERS). Drug Safety. 37(11). 971–980. 85 indexed citations

6.

Hoffman, Keith B., et al.. (2014). The Weber Effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): Analysis of Sixty-Two Drugs Approved from 2006 to 2010. Drug Safety. 37(4). 283–294. 131 indexed citations

7.

Hoffman, Keith B., Christina N. Kraus, Mo Dimbil, & Beatrice A. Golomb. (2012). A Survey of the FDA's AERS Database Regarding Muscle and Tendon Adverse Events Linked to the Statin Drug Class. PLoS ONE. 7(8). e42866–e42866. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact